An interventional study of Blephex and MiboFlo in Meibomian Gland Dysfunction, Dry Eye and Posterior Blepharitis, sponsored by University of the Incarnate Word. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-08.
Sponsored by University of the Incarnate Word · Not applicable, Interventional, and Treatment
Among 63 studies in Meibomian Gland Dysfunction with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Meibomian Gland Dysfunction · United States.
Among the 63 studies in Meibomian Gland Dysfunction with a site in United States, this one is the 56th largest by enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2015, is one of 42 with no phase, and was the 17th registered.
172 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.
Browse Meibomian Gland Dysfunction studies →7 of the 63 studies in Meibomian Gland Dysfunction with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
University of Alabama at Birmingham · Sites in United States
University of California, Berkeley · Sites in United States
University of Houston · Sites in United States
Illinois College of Optometry · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stop at 75 or younger; 1 take children under 18; 1 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 4 7
First in 2008; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 50 across 138 interventional studies indexed under Meibomian Gland Dysfunction.
Median enrollment 44 across the 61 interventional studies, 33 across the 2 observational. Of the 44 that completed or were terminated, 29 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 63 have an industry lead sponsor. The 10 most frequent:
University of the Incarnate Word is the lead sponsor of 15 studies on the registry; none are open to participants now.
University of the Incarnate Word has 5 studies filed under Meibomian Gland Dysfunction — fewer than ten, so there is no comparison to draw.
6 of the studies in Meibomian Gland Dysfunction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07229001Illinois College of OptometryTreating Meibomian Gland Disease in a Pediatric Population | 2026-12-30 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07579156University of Alabama at BirminghamTearCare in Young Adults | 2027-08-01 |
Among the 63 studies in Meibomian Gland Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to compare which treatment - BlephEx or MiBoFlo - will be a better option for patients suffering from dry eye secondary to Meibomian Gland dysfunction.
The investigators have previously studied the effect of the BlephEx instrument (debridement of lid debris) in relieving signs and symptoms of blepharitis (Connor CG et al, ARVO 2014). This previous study demonstrated positive results from the BlephEx treatment. Warming the eyelids (e.g., using warm wash cloths) still remains a viable treatment option for this disease. However, patients are often non-compliant with warm compress therapy due to the requirement of performing it at least twice per day. The MiBoflo delivers uniform and consistent amounts of heat to the eyelid. It is suggested that two treatments over 30 days is adequate to relieve signs and symptoms of Meibomian gland dysfunction. This equipment is currently used in optometric practices in this country.
There are no clinical studies comparing BlephEx and MiBoflo as treatment options for blepharitis. Hence, the current study will provide new and useful information on which treatment option may be better for treating blepharitis and Meibomian gland dysfunction. Part of this study will also investigate if a combination of BlephEx and MiBoflo treatments is more beneficial to the patient. The data generated will directly benefit clinical practice and impact several millions of patients who suffer from this Blepharitis and / or Meibomian gland dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with the BlephEx instrument (lid margin exfoliation)
Device: Blephex
Treatment with the MiboFlo equipment (heat therapy to eyelids)
Device: MiboFlo
Lid margin exfoliation
Lid warming treatment
Ocular irritation symptoms (OSDI Questionnaire score)
Time frame: one month
Tear break-up
Time frame: one month
Plan to share: No — No plan to share IPD to other researchers
No publications or documents are linked to this record.
The record gives a start of May 2015, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of the Incarnate Word